Biomarker-based corticosteroid adjustment in severe asthma: a modified Delphi consensus
Main Authors: | Nicola E. Gallagher, Catherine E. Hanratty, Marc Humbert, Elisabeth Bel, Ratko Djukanovic, Valerie Hudson, Nile Amos, Liam G. Heaney |
---|---|
Format: | Article |
Language: | English |
Published: |
European Respiratory Society
2018-12-01
|
Series: | ERJ Open Research |
Online Access: | http://openres.ersjournals.com/content/4/4/00081-2018.full |
Similar Items
-
Corticosteroid tapering with benralizumab treatment for eosinophilic asthma: PONENTE Trial
by: Andrew Menzies-Gow, et al.
Published: (2019-09-01) -
A randomised pragmatic trial of corticosteroid optimization in severe asthma using a composite biomarker algorithm to adjust corticosteroid dose versus standard care: study protocol for a randomised trial
by: Hanratty, CE, et al.
Published: (2018) -
Using biomarkers to adjust corticosteroid dose in patients with severe asthma
by: Thomas L. Jones
Published: (2021-03-01) -
Severe eosinophilic asthma: a roadmap to consensus.
by: Buhl, R, et al.
Published: (2017) -
The cost of systemic corticosteroid-induced morbidity in severe asthma: a health economic analysis
by: L. E. Barry, et al.
Published: (2017-06-01)